Total pharma industry M&A deals in February 2019 worth $28.83bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 68.7% over the previous month and a drop of 39% when compared with the last 12-month average, which stood at $20.74bn.

Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $27.72bn. At the country level, the US topped the list in terms of deal value at $26.41bn.

In terms of volumes, North America emerged as the top region for pharma industry M&A deals globally, followed by Asia-Pacific and then Europe.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The top country in terms of M&A deals activity in February 2019 was the US with 14 deals, followed by China with four and Switzerland with two.

In 2019, as of the end of February 2019, pharma M&A deals worth $120.91bn were announced globally, marking an increase of 196.8% year on year.

Pharma industry M&A deals in February 2019: Top deals

The top five pharma industry M&A deals accounted for 96.5% of the overall value during February 2019.

The combined value of the top five pharma industry M&A deals stood at $27.81bn, against the overall value of $28.83bn recorded for the month. The top announced pharma industry M&A deal tracked by GlobalData in February 2019 was Danaher‘s $21.4bn asset transaction with General Electric.

In second place was the $4.3bn acquisition of Spark Therapeutics by F. Hoffmann-La Roche and in third place was Ipsen‘s $1.3bn acquisition of Clementia Pharmaceuticals.

The $510m acquisition of CiToxLAB Group by Charles River Laboratories International and Merck Sharp & Dohme’s acquisition of Immune Design for $300m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.